Allogeneic hematopoietic stem cell transplantation for myelofibrosis

Blood

Volumn 102, Issue 12, 2003, Pages 3912-3918

  Deeg, H Joachim ^a   Gooley, Theodore A ^b   Flowers, Mary E D ^b   Sale, George E ^b   Slattery, John T ^b   Anasetti, Claudio ^b   Chauncey, Thomas R ^b   Doney, Kristine ^b   Georges, George E ^b   Kiem, Hans Peter ^b   Martin, Paul J ^b   Petersdorf, Effie W ^b   Radich, Jerald ^b   Sanders, Jean E ^b   Sandmaier, Brenda M ^b   Warren, E Houston ^b   Witherspoon, Robert P ^b   Storb, Rainer ^b   Appelbaum, Frederick R ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; ANTINEOPLASTIC AGENT; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ERYTHROPOIETIN; HYDROXYUREA; INTERFERON; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOTRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CHIMERA; CHROMOSOME ABERRATION; CONFIDENCE INTERVAL; DRUG FATALITY; DUPRIEZ SCORE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOFIBROSIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; SCHOOL CHILD; SCORING SYSTEM; SURVIVAL RATE; THROMBOCYTHEMIA; UNITED STATES; WHOLE BODY RADIATION;

EID: 10744230038     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-1856     Document Type: Article

References (32)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
2. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34:29-39.
3. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656-664.
4. Hoffman R. Agnogenic myeloid metaplasia. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basice Principles and Practice. New York, NY: Churchill Livingstone; 2000:1172-1188.
5. Hasselbalch H, Jensen BA. Prognostic factors in idiopathic myelofibrosis: a simple scoring system with prognostic significance. Eur J Haematol. 1990;44:172-178.
6. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75:4-9.
7. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-1018.
8. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95:2226-2233.
9. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495-3503.
10. Rozman C, Giralt M, Feliu E, Rubio D, Cortes M-T. Life expectancy of patients with chronic non-leukemic myeloproliferative disorders. Cancer. 1991;67:2658-2663.
11. Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol. 1997;98:1010-1016.
12. Anderson JE, Tefferi A, Craig F, et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood. 2001;98:586-593.
13. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood. 1999;93:2831-2838.
14. Guardiola P, Esperou H, Cazals-Hatem D, et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br J Haematol. 1997;98:1004-1009.
15. Przepiorka D, Giralt S, Khouri I, Champlin R, Bueso-Ramos C. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol. 1998;57:24-28.
16. Singhal S, Powles R, Treleaven J, Pollard C, Lumley H, Mehta J. Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant. 1995;16:743-746.
17. Jurado M, Deeg HJ, Gooley T, et al. Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia. Br J Haematol. 2001;112:392-396.
18. Petersdorf EW, Hansen JA. A comprehensive approach for typing the alleles of the HLA-B locus by automated sequencing. Tissue Antigens. 1995;46:73-85.
19. Petersdorf EW, Anasetti C, Martin PJ, Hansen JA. Impact of molecular histocompatibility typing on outcome of unrelated donor hematopoietic cell transplantation. Curr Opin Organ Transplant. 2002;7:279-285.
20. Petersdorf EW, Anasetti C, Martin PJ, Hansen JA. Tissue typing in support of unrelated hemtopoieitc cell transplantation. Tissue Antigens. 2003;61:1-11.
21. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055-3060.
22. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monitoring. 1998;20:543-549.
23. Jurado M, Deeg HJ, Storer B, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant. 2002;8:161-169.
24. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100:1201-1207.
25. Deeg HJ, Yamaguchi M. Acute graft-versus-host disease. In: Atkinson K, ed. Clinical Bone Marrow and Blood Stem Cell Transplantation. Cambridge, United Kingdom: Cambridge University Press; 2000;681-699.
26. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267-276.
27. Petersdorf EW, Longton GM, Anasetti C, et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood. 1997;89:1818-1823.
28. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
29. Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98:3249-3255.
30. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;113:763-771.
31. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002;99:2255-2258.
32. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631-637.